Back to top

Image: Bigstock

Mallinckrodt plc

Read MoreHide Full Article

Mallinckrodt’s hospital franchise (Inomax and Ofirmev) has gained traction which is positively impacting performance. The spin-off of the generic business appears to be a step in the right direction as this will enable Mallinckrodt to focus better on the branded business, which promises potential. Mallinckrodt has streamlined its business of late to focus better on its innovative medicines and therapies. Shares have outperformed the industry in the last twelve months. The company has been involved in quite a few lawsuits for its alleged role in the current opioid epidemic in the United States through its marketing and promotion practices. However, pipeline setbacks continue to weigh on the company. The CRL for stannsoporfin was disappointing. Acthar, Mallinckrodt’s largest product, is being impacted by the residual impact of the previously reported patient withdrawal issues. Estimates are up by 2 cents ahead of Q4 results.

Published in